Opendata, web and dolomites

CHAMPION SIGNED

Cartilage Healing Approach Merging Polymer InnOvation with Nature

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CHAMPION project word cloud

Explore the words cloud of the CHAMPION project. It provides you a very rough idea of what is the project "CHAMPION" about.

cartilage    pursuit    synchronized    commercialization    poor    action    defects    gradually    patients    human    cell    alternative    promise    prochondrogenic    channels    gained    replaced    surgery    implant    regulatory    focal    annually    ce    shape    total    market    arthroscopic    joint    multiple    marrow    completing    requiring    stem    mode    optimal    denatured    polyethylene    outcome    resorbable    complexity    inwards    migration    treatments    biologicals    knee    light    shelf    limited    painful    bone    ready    fibrinogen    acellular    clinical    replacement    body    symptomatic    hyaline    quick    treatment    preventing    glycol    optimizing    microfracture    re    stimulation    undesired    situ    off    interventions    injuries    gelrinc    unlike    procedure    limiting    implants    outside    risks    right    osteoarthritis    barrier    cellular    conforming    realized    cells    injury    afflicts    ultraviolet    rate    microenvironment    failed    centres    time    mark    successful    therapeutic    defect    differentiate    frequent    longterm    elusive    cured    resorbs    benefit    excellence    chondrocytes    harnesses    2017    liquid    designed    entrance    million    degradation    form    trials    implantation    articular   

Project "CHAMPION" data sheet

The following table provides information about the project.

Coordinator
REGENTIS BIOMATERIALS LTD 

Organization address
address: HA ILAN STREET 2 NORTHERN INDUSTRIAL ZONE
city: OR AKIVA
postcode: 30600
website: www.regentis.co.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙121˙700 €
 EC max contribution 2˙185˙190 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGENTIS BIOMATERIALS LTD IL (OR AKIVA) coordinator 2˙185˙190.00

Map

 Project objective

Cartilage injury afflicts over one million patients annually in Europe. Focal knee cartilage defects are as painful and limiting as osteoarthritis and can lead further degradation requiring total knee replacement surgery. Focal knee cartilage injuries are typically treated by bone marrow stimulation (Microfracture) which has limited benefit due to a high failure rate, poor longterm outcome and frequent required re-interventions. Alternative therapeutic products in the form of cellular/biologicals treatments have failed due to complexity and multiple surgery risks. With the promise of cell-based procedures not realized, the pursuit of an optimal treatment for symptomatic articular cartilage defects in the knee joint remains elusive. GelrinC is a simple, off-the-shelf treatment for focal injuries in the knee cartilage. It is a ready-to-use liquid cured in-situ by ultraviolet light to form a resorbable implant conforming to the shape and depth of the defect. Unlike other acellular implants, GelrinC was designed to support the formation of hyaline cartilage through a unique Mode-of-Action: Formation of a cell barrier thus preventing migration of undesired cells into the defect. At the same time, GelrinC harnesses the established prochondrogenic potential of polyethylene glycol, its major component, to provide the right microenvironment for the body’s own stem cells to differentiate into chondrocytes. Due to the presence of the denatured human fibrinogen in GelrinC, the implant resorbs from the outside inwards and thus is gradually replaced with new hyaline-like cartilage in a synchronized process. GelrinC gained a CE mark in 2017 and it is regulatory ready for commercialization in Europe. The next steps allowing quick, successful market entrance are optimizing the production process, completing a phase III clinical trials,improving the procedure towards arthroscopic implantation; and creating commercialization channels including centres of excellence in Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHAMPION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CHAMPION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More